Clozapine
Brand names: Clozapine, Clozapine Odt, Clozaril, Versacloz
At a glance
- Medicare prescriptions, 2024
- 1,092,341
- Medicare drug cost
- $95.4M
- Average cost per prescription
- $87.31
- Clinicians who prescribed it
- 18,012
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
VERSACLOZ is an atypical antipsychotic indicated for: Treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, VERSACLOZ should be used only in patients who have failed to respond adequately to standard antipsychotic treatment. Reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior.
From the FDA-approved prescribing information (label dated September 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: SEVERE NEUTROPENIA; ORTHOSTATIC HYPOTENSION, BRADYCARDIA, AND SYNCOPE; SEIZURE; MYOCARDITIS, PERICARDITIS, AND CARDIOMYOPATHY; INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Psychiatry 50.0%
- Psychiatric Nurse Practitioners 28.4%
- Nurse Practitioners 6.6%
- Internal Medicine 3.8%
- Physician Assistants 3.4%
- Family Medicine 2.6%
- Child & Adolescent Psychiatry 2.0%
- Neurology 0.9%
- Geriatric Medicine 0.8%
- Pharmacists 0.2%
- Hospitalist 0.2%
- General Practice 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 5% from 2019 to 2024.
Biggest change by state since 2019
- Arizona +20%
- Utah +12%
- Colorado +7%
- Nebraska +4%
- Texas +2%
- Illinois (smallest change) −21%
- Missouri (smallest change) −20%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Cardinal Health 107, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 100 mg | yellow round tablet, 10 mm, scored to split in 2 | C C 57 |
Mylan Pharmaceuticals Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | orange round tablet, 9 mm, scored to split in 2 | C 7 M |
| 50 mg | green round tablet, 6 mm, scored to split in 2 | C72 M |
| 100 mg | green round tablet, 9 mm, scored to split in 2 | C11 M |
| 200 mg | green round tablet, 11 mm, scored to split in 2 | C73 M |
Northstar Rx LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | yellow round tablet, 6 mm, scored to split in 2 | C C 54 |
| 50 mg | yellow round tablet, 8 mm, scored to split in 2 | C C 55 |
| 100 mg | yellow round tablet, 10 mm, scored to split in 2 | C C 57 |
| 200 mg | yellow oval tablet, 17 mm, scored to split in 2 | C C 71 |
Trupharma LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 50 mg | yellow suspension | |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $3,646 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Mylan Inc. $3,646
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
1 recall since 2020
- Jun 2020 · Aurobindo Pharma USA Inc. · Class II
Presence of foreign tablet: Consumer complaint of Clozapine Tablets 50mg being present in 500 count bottles of Clozapine Tablets USP 100mg.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.